Crown laboratories extension of tender offer to acquire revance therapeutics, inc.

Johnson city, tenn. , jan. 13, 2025 /prnewswire/ -- crown laboratories, inc. ("crown"), a privately held, global innovative leader in the skincare industry, today announced that, at the request of revance therapeutics, inc., ("revance") (nasdaq: rvnc), it has extended the expiration of its cash tender offer to acquire all of the issued and outstanding shares of common stock, par value $0.001 per share ("shares") of revance, at a price of $3.10 per share in cash, without interest and less any applicable tax withholding.
RVNC Ratings Summary
RVNC Quant Ranking